Haggai Bar-Yoseph1,2, Haneen Daoud3, Dana Ben Hur4,3, Yehuda Chowers4,5,6, Matti Waterman4,5. 1. Department of Gastroenterology, Rambam Health Care Campus, 8th Haalia Hashnia st., 3109601, Haifa, Israel. haggaiby@gmail.com. 2. Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. haggaiby@gmail.com. 3. Department of Internal Medicine H, Rambam Health Care Campus, 8th Haalia Hashnia st., 3109601, Haifa, Israel. 4. Department of Gastroenterology, Rambam Health Care Campus, 8th Haalia Hashnia st., 3109601, Haifa, Israel. 5. Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. 6. Clinical Research Institute, Rambam Health Care Campus, Haifa, Israel.
Abstract
BACKGROUND: Corticosteroids (CS) therapy to Clostridioides difficile infection (CDI) in inflammatory bowel disease (IBD) flares may worsen CDI outcomes. AIM: Assess the impact of early CS exposure on outcomes of IBD patients diagnosed with CDI. METHODS: Retrospective study of IBD patients admitted with first-time CDI between 2002 and 2018. Comparisons were made based on CS exposure 48 h from admission. Patients were further subdivided to 5 groups based on CS-antibiotics temporal exposure. The primary outcome was all-cause mortality or colectomy within 3 months. Secondary outcomes were colectomy and mortality rates at 1 year, length of stay, readmissions, bacteremia, and diarrhea improvement by day 7/discharge. Cox proportional hazard model and Kaplan-Meier curves were used to assess the effects on survival. Logistic and ordinal regressions were used to assess primary and secondary outcomes. RESULTS: One hundred thirteen patients (64 CD, 46 UC, and 3 IBDU) were included, 82 (72.5%) received early CS. At baseline, CRP was significantly lower and albumin was higher in the group not exposed to early CS. At 3 months, 4 (4.8%) patients required colectomy and 6 (5.8%) died (p = NS). Length of stay was significantly reduced among patients not exposed to early CS. All other endpoints were not associated with CS exposure. In subgroup analysis, the primary outcome was not significantly different among the sub-groups. Mortality rate at 1 year was significantly lower in patients who did not receive antibiotics for CDI. CONCLUSION: Early CS therapy in IBD patients hospitalized with CDI is not associated with worse clinical outcomes. However, additional prospective research is required.
BACKGROUND:Corticosteroids (CS) therapy to Clostridioides difficile infection (CDI) in inflammatory bowel disease (IBD) flares may worsen CDI outcomes. AIM: Assess the impact of early CS exposure on outcomes of IBDpatients diagnosed with CDI. METHODS: Retrospective study of IBDpatients admitted with first-time CDI between 2002 and 2018. Comparisons were made based on CS exposure 48 h from admission. Patients were further subdivided to 5 groups based on CS-antibiotics temporal exposure. The primary outcome was all-cause mortality or colectomy within 3 months. Secondary outcomes were colectomy and mortality rates at 1 year, length of stay, readmissions, bacteremia, and diarrhea improvement by day 7/discharge. Cox proportional hazard model and Kaplan-Meier curves were used to assess the effects on survival. Logistic and ordinal regressions were used to assess primary and secondary outcomes. RESULTS: One hundred thirteen patients (64 CD, 46 UC, and 3 IBDU) were included, 82 (72.5%) received early CS. At baseline, CRP was significantly lower and albumin was higher in the group not exposed to early CS. At 3 months, 4 (4.8%) patients required colectomy and 6 (5.8%) died (p = NS). Length of stay was significantly reduced among patients not exposed to early CS. All other endpoints were not associated with CS exposure. In subgroup analysis, the primary outcome was not significantly different among the sub-groups. Mortality rate at 1 year was significantly lower in patients who did not receive antibiotics for CDI. CONCLUSION: Early CS therapy in IBDpatients hospitalized with CDI is not associated with worse clinical outcomes. However, additional prospective research is required.
Authors: A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis Journal: J Crohns Colitis Date: 2010-01-15 Impact factor: 9.071
Authors: Henit Yanai; Geoffrey C Nguyen; Laura Yun; Oscar Lebwohl; Udayakumar Navaneethan; Christian D Stone; Leyla Ghazi; Paul Moayyedi; Jeffrey Brooks; Charles N Bernstein; Shomron Ben-Horin Journal: Inflamm Bowel Dis Date: 2010-11-18 Impact factor: 5.325
Authors: Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun Journal: Am J Gastroenterol Date: 2013-02-26 Impact factor: 10.864
Authors: Harminder Singh; Zoann Nugent; B Nancy Yu; Lisa M Lix; Laura E Targownik; Charles N Bernstein Journal: Gastroenterology Date: 2017-05-04 Impact factor: 22.682
Authors: A N Ananthakrishnan; R Guzman-Perez; V Gainer; T Cai; S Churchill; I Kohane; R M Plenge; S Murphy Journal: Aliment Pharmacol Ther Date: 2012-02-23 Impact factor: 8.171
Authors: Fernanda C Lessa; Yi Mu; Wendy M Bamberg; Zintars G Beldavs; Ghinwa K Dumyati; John R Dunn; Monica M Farley; Stacy M Holzbauer; James I Meek; Erin C Phipps; Lucy E Wilson; Lisa G Winston; Jessica A Cohen; Brandi M Limbago; Scott K Fridkin; Dale N Gerding; L Clifford McDonald Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245